Curis, Inc. · NASDAQ:CRIS
Curis — Investor Presentation (June 2005)
46 slides from Curis's investor presentation, Jun 20, 2005
Slide 1: Curis, Inc. Corporate Overview June 20, 2005
CURIS TM Curis, Inc. (NASDAQ: CRIS) Corporate Overview June 20, 2005
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Curis’ drug discovery and development programs. Such statements may contain the words “believes”, “expects”, “antici
Slide 3: Presentation Outline
Presentation Outline Business Model Technology Overview Collaborations and Product Candidates Patents/Financials
Slide 4: Curis Business Strategy
Curis Business Strategy Collaboration strategy improves probability of success Portfolio approach results in product diversity (i.e., technology platform, compound type, and target indication) Payments from collaborators lessen future dependence on capital markets • Cash milestones under top four de
Slide 5: Curis Business Strategy
Curis Business Strategy Collaboration strategy improves probability of success Portfolio approach results in product diversity (i.e., technology platform, compound type, and target indication) Payments from collaborators lessen future dependence on capital markets • Cash milestones under top four de
Slide 6: Curis Collaborative / Licensed Programs
Curis Collaborative / Licensed Programs Collaborator Technology Compound Primary Indication Genentech CURIS Hh pathway Small molecule Basal cell carcinoma antagonist (topical formulation) Genentech Hh pathway Sm. mol. Antag. Other solid tumors and antibodies (systemic formulation) Wyeth Hh pathway S
Slide 7: Curis Business Strategy
Curis Business Strategy CURIS TM Collaboration strategy improves probability of success Portfolio approach results in product diversity (i.e., technology platform, compound type, and target indication) Payments from collaborators lessen future dependence on capital markets • Cash milestones under to
Slide 8: Curis Proprietary Programs
Curis Proprietary Programs CURIS TM Curis Program Technology Compound Primary Indication CURIS Hh pathway Small molecule Hair growth agonist (topical delivery) CURIS Hh pathway Nucleic Acid Cardiovascular (local delivery) CURIS Discovery Small Spinal Muscular Screening molecule Atrophy1 CURIS Discov
Slide 9: Presentation Outline
Presentation Outline CURIS TM Business Model Technology Overview Collaborations and Product Candidates Patents/Financials/Summary
Slide 10: Stem Cells are Regulated by Signaling Pathways
Stem Cells are Regulated by Signaling Pathways to Build the Body’s Tissues and Organ Systems Stem Progenitor Specialized Cells Cells Cells Signaling Pathways
Slide 11: Mutations in Stem Cells can Lead to Proliferation of Cancer Cells
Mutations in Stem Cells can Lead to Proliferation of Cancer Cells Stem Cells Unregulated Signaling Pathways CANCER
Slide 12: Pathway Antagonists can Block Cancer Growth
Pathway Antagonists can Block Cancer Growth Stem Cells Signaling Pathway Antagonist Unregulated Signaling Pathways CANCER
Slide 13: Presentation Outline
Presentation Outline Business Model Technology Overview Collaborations and Product Candidates Patents/Financials/Summary
Slide 14: Hedgehog Pathway Antagonist Program
Hedgehog Pathway Antagonist Program Basal Cell Carcinoma and other Solid Tumor Cancers Collaboration with Genentech
Slide 15: Genentech Hh Antagonist Collaboration
Genentech Hh Antagonist Collaboration Established: June 2003 Deal structure: $8.5 million up-front payment, development milestones, product royalties, minimum two years R&D support, BCC co-development option in U.S. Primary indications: Topical treatment for basal cell carcinoma (co-development prog
Slide 16: Genentech Hedgehog Antagonist Collaboration: Recent Progress
Genentech Hedgehog Antagonist Collaboration: Recent Progress Genentech doubles the number of Curis personnel on Hedgehog antagonist program from 8 to 16 Curis personnel are supporting systemic solid tumor program Genentech extends research funding under the Hedgehog antagonist program from June 2005
Slide 17: Hedgehog Antagonists can Eliminate Basal Cell Carcinoma
Hedgehog Antagonists can Eliminate Basal Cell Carcinoma Basal Cell Carcinoma Model Untreated skin cancer model treated w/ topical small molecule Hh antagonist from Williams et al, 2003
Slide 18: Basal Cell Carcinoma (BCC) Genentech Curis Co-Development
Basal Cell Carcinoma (BCC) Genentech Curis Co-Development Co-development: Profit sharing structure commensurate with cost-sharing contributions; equal participation option exercised February 2005 BCC Phase I initiation: April 2005 Disease incidence: 800,000 to 1 million cases annually in the U.S.* M
Slide 19: BCC – Hh Antagonist Pilot Human Clinical Study
BCC – Hh Antagonist Pilot Human Clinical Study Study goal: To assess the potential of a Hedgehog (Hh) pathway antagonist as a treatment for basal cell carcinoma (BCC) Hh antagonist: Cyclopamine Study design: Four patients with established BCCs, who were scheduled for excision surgery, treated topica
Slide 20: BCC – Hh Antagonist Pilot Human Clinical Study
BCC – Hh Antagonist Pilot Human Clinical Study Placebo Treated Day 2 Untreated Tumor Cyclopamine Treated Day 2 from Ta and Avci, 2004
Slide 21: BCC – Hh Antagonist Pilot Human Clinical Study
BCC – Hh Antagonist Pilot Human Clinical Study Study results: All cyclopamine-treated tumors regressed rapidly Histological analysis showed inhibition of tumor cell proliferation and induction of tumor cell apoptosis No adverse effects were noted on normal skin tissue Results suggest that transient
Slide 22: Other Cancers Associated with Abnormal Expression of Hedgehog
Other Cancers Associated with Abnormal Expression of Hedgehog Medulloblastoma1 Small Cell Lung Cancer 2 Pancreatic Carcinoma 3,4 Stomach Cancer 4 Esophageal Cancer 4 Colorectal Cancer 5 Prostate Cancer 6,7,8 Breast Cancer 9 1 Romer et al, 2004, 2 Watkins et al, 2003, 3 Thayer et al, 2003, 4 Berman e
Slide 23: Abnormal Hedgehog Expression Supports Growth of Certain Cancers
Abnormal Hedgehog Expression Supports Growth of Certain Cancers Certain Cancers Hedgehog Protein Adjacent Stromal Cells Angiogenesis Factors Growth Factors VEGF Ang-1 Ang-2 IGF-I BDNF NGF
Slide 24: Curis Antagonist Technologies Block the Hedgehog Pathway
Curis Antagonist Technologies Block the Hedgehog Pathway Certain Cancers Small Molecules Hedgehog Protein Antibodies Adjacent Stromal Cells Angiogenesis Factors Growth Factors VEGF Ang-1 Ang-2 IGF-I BDNF NGF
Slide 25: Genentech Hedgehog Antagonist Collaboration: Anticipated Milestones
Genentech Hedgehog Antagonist Collaboration: Anticipated Milestones Data from BCC Curis projects first half Phase I trial of 2006 Selection of lead drug Curis estimates 2005 development candidate for other solid tumors First IND filing Curis estimates 2006 for other solid tumors (cash milestone paym
Slide 26: Hedgehog Pathway Agonist Program
Hedgehog Pathway Agonist Program Neurological and other Disorders Collaboration with ©2005 Curis Inc. ©2003
Slide 27: Wyeth Hedgehog Agonist Collaboration
Wyeth Hedgehog Agonist Collaboration Established: January 2004 Deal structure: $3 million up-front payment, development milestones of up to $170 million, product royalties, minimum two years R&D support (1) Primary indications: Stroke and other neurological disorders (1) – Development milestone tota
Slide 28: Hedgehog Pathway is Activated in Response to Nerve Injury
Hedgehog Pathway is Activated in Response to Nerve Injury Relative Level of Hedgehog mRNA BLUE staining denotes presence of Hedgehog 600 400 200 0 Day 0 Day 1 0 1 3 7 13 Time After Injury (days) Source: internal Curis research
Slide 29: Small Molecule Hedgehog Agonist Reduces Infarct Size in Stroke Model
Small Molecule Hedgehog Agonist Reduces Infarct Size in Stroke Model Stroke Neuroprotection Model Infarct Area Vehicle Hedgehog Agonist Source: internal Curis research
Slide 30: Wyeth Hedgehog Agonist Collaboration: Anticipated Milestones—Market
Wyeth Hedgehog Agonist Collaboration: Anticipated Milestones—Market Estimated IND filing: Curis estimates late 2006 (cash milestone payment) Disease incidence: Approximately 700,000 patients suffer a stroke each year in U.S.1 Marketing advantage: Presently no effective therapies for treating stroke
Slide 31: BMP Pathway Program
BMP Pathway Program Kidney Disease and Associated Disorders Licensed to a subsidiary of
Slide 32: Ortho Biotech (J&J) BMP License
Ortho Biotech (J&J) BMP License Established: November 2002 Transitioned to Centocor in 2005 Deal structure: $3.5 million up-front payment, development milestones including $30 million on NDA approval, product royalties Primary indications: Chronic kidney disease and disorders associated with end sta
Slide 33: The BMP-7 Pathway Promotes Kidney Function
The BMP-7 Pathway Promotes Kidney Function and Prevents Kidney Disease Related Disorders BMP-7 maintains kidney structure and function BMP-7 promotes skeletal mineralization BMP-7 prevents vascular calcification
Slide 34: BMP-7 Prevents Development of Metabolic Bone Disease and Vascular Calcification
BMP-7 Prevents Development of Metabolic Bone Disease and Vascular Calcification Chronic Kidney Disease Model Bone Formation Rate [GRAPHIC] *p<0.05 vs normal **p<0.05 vs disease Normal Disease Disease Untreated + BMP-7 Vascular Calcification 7 6 5 4 3 2 1 0 ***p<0.01 Disease Disease + Untreated BMP-7
Slide 35: Ortho Biotech (J&J) BMP License: Anticipated Milestone - Market
Ortho Biotech (J&J) BMP License: Anticipated Milestone - Market Estimated IND filing: 2007 - 2008 1 Disease incidence: Approximately 423,000 patients have end-stage renal disease in U.S.2 Marketing advantage: Presently no effective therapies for treating renal disease and associated complications 1
Slide 36: Undisclosed Pathway Antagonist/Agonist Program
Undisclosed Pathway Antagonist/Agonist Program Collaboration with
Slide 37: Genentech Undisclosed Pathway Antagonist/Agonist Program
Genentech Undisclosed Pathway Antagonist/Agonist Program Established: April 2005 Deal structure: $3 million up-front payment, development milestones of up to $140 million, product royalties, minimum two years R&D support ($6M) (1) Primary indications: Antagonist: not disclosed Agonist: not disclosed
Slide 38: Curis Proprietary Programs
Curis Proprietary Programs Curis Program Technology Compound Primary Indication Hh pathway Small molecule Hair growth agonist (topical delivery) Hh pathway Nucleic Acid Cardiovascular (local delivery) Discovery Small Spinal Muscular Screening molecule Atrophy1 Discovery Small Not disclosed Screening
Slide 39: Hair Growth Regulation
Hair Growth Regulation (Hedgehog Agonist Technologies) Development by
Slide 40: Hedgehog Pathway Regulates Initiation and Maintenance of Hair Growth
Hedgehog Pathway Regulates Initiation and Maintenance of Hair Growth Hair Growth Model Day 4 Day 4 Day 7 Stimulated Hair Follicles Replicating Hair Follicle Cells New Hair Shaft Growing Source: internal Curis research
Slide 41: Small Molecule Hedgehog Agonist Promotes Hair Growth
Small Molecule Hedgehog Agonist Promotes Hair Growth Vehicle Treated Agonist Treated One dose, topical application, day 13 after treatment Source: internal Curis research
Slide 42: Presentation Outline
Presentation Outline Business Model Technology Overview Collaborations and Product Candidates Patents/Financials
Slide 43: Strong Intellectual Property Position
Strong Intellectual Property Position Approximately 200 US patents issued or allowed and over 100 pending in U.S. Approximately 300 foreign patents issued or allowed and 350 foreign patents pending Compositions of matter covering signaling proteins, receptors, antibodies, small molecule agonists and
Slide 44: Financial Data
Financial Data March 31, 2005 (amounts in 000’s except per share data) Cash, cash equivalents, investments $ 46,900 Accounts receivable $ 2,100 Convertible debt $ 2,500 Other debt $ 2,300 Shareholders’ equity $ 47,100 Basic shares outstanding 47,900 Fully diluted shares outstanding 59,000 YTD loss p
Slide 45: Financial Guidance
Financial Guidance Cash life Mid-20071 BCC Co-development costs to Ph II completion (Mid 2007) $20 million 2005 Guidance: Cash at December 31, 2005 $36 - $39 million Gross revenues $11 - $13 million BCC Co-development costs $8.5 - $9 million 2 Research and Development $13 - $15 million Administratio
Slide 46: Curis, Inc. Corporate Overview
Curis, Inc. (NASDAQ: CRIS) Corporate Overview June 20, 2005